AARD vs RYTM vs VNDA vs VKTX vs IQV

For growth investors, Rhythm Pharmaceuticals, Inc.

(RYTM) is the stronger pick with 45. 8% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 23. 1x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Aardvark Therapeutics, Inc. Common Stock (AARD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +370. 6%, compared to -74. 6% for Aardvark Therapeutics, Inc. Common Stock (AARD). Over 10 years, the gap is even starker: VKTX returned +22. 0% versus AARD's -72. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vanda Pharmaceuticals Inc.

(VNDA) is the lower-risk stock at 1. 01β versus Aardvark Therapeutics, Inc. Common Stock's 2. 70β — meaning AARD is approximately 167% more volatile than VNDA relative to the S&P 500. On balance sheet safety, Viking Therapeutics, Inc. (VKTX) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rhythm Pharmaceuticals, Inc.

(RYTM) is pulling ahead at 45. 8% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Rhythm Pharmaceuticals, Inc. grew EPS 28. 3% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — VNDA leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AARD: 705.

8% to $29. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IQVIA Holdings Inc.

(IQV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16), +177. 5% 10Y return). Aardvark Therapeutics, Inc. Common Stock (AARD) carries a higher beta of 2. 70 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IQV: +177. 5%, AARD: -72. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AARD is a small-cap quality compounder stock; RYTM is a small-cap high-growth stock; VNDA is a small-cap quality compounder stock; VKTX is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.